First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.
Epistemonikos ID: c306e2e491c23d8714ec2a497abc16ab19ab3f1d
First added on: May 06, 2024